Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.
Conditions
Interventions
Epcoritamab
Locations
1
United States
University of Cincinnati
Cincinnati, Ohio, United States
Start Date
August 22, 2025
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2029
Last Updated
January 6, 2026
NCT06846671
NCT07523555
NCT07030400
NCT06859424
NCT05589896
NCT06043011
Zulfa Omer, MD
CONTACT
Lead Sponsor
Zulfa Omer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions